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How to manage risk in cases of papillary thyroid
microcarcinomas (PTMC), defined as papillary thyroid
carcinomas (PTC) of size B1.0 cm,1 has been controver-
sial. Conventional wisdom dictates that these are low-risk
cancers that are virtually free of mortality and should
therefore be conservatively managed. Also in support of
conservative management of PTMC are the potentially
adverse outcomes of aggressive treatments, such as surgi-
cal damage to the recurrent laryngeal nerve and parathyroid
glands from thyroid surgery and the development of second
primary cancers from radioiodine treatments.2,3 It is even
acceptable in some practices to forgo treatments of patients
with PTMC.4 On the other side of the coin, however, is the
well-recognized risk that PTMC can progress with a sig-
nificant recurrence rate and even mortality in some
patients.5–7 This is true particularly in the presence of high-
risk clinicopathological factors that are classically known
to be associated with a poor prognosis in conventional
thyroid cancers. These include extrathyroidal extension,
lymph node metastasis, and high TNM stages.8–12 Given
these divided results, it appears that a subgroup of PTMC is
inherently aggressive and predestined to progress.
Although opinions often differ on how to manage
PTMC,6,7 there is little argument that the subgroup of
patients with PTMC with high potential for poor prognosis
should receive relatively aggressive initial treatments (e.g.,
total thyroidectomy, central neck dissection, or radioiodine
ablation as opposed to lobectomy, no neck dissection, or no
radioiodine ablation, respectively) and vigilant follow-up
for disease recurrence after initial treatments. The chal-
lenge, however, often lies in the difficulty of identifying
this subgroup of PTMC based on the classical
clinicopathological criteria, particularly preoperatively,
when the pathological characteristics of the tumor are
virtually unknown. Therefore, it is often not a straightfor-
ward task to determine the appropriate level and extent of
the initial treatment for an individual patient with PTMC
that has been identified ultrasonographically and confirmed
cytologically.
In recent years, the T1799A BRAF mutation has emerged
as a promising prognostic factor in the risk stratification of
PTC.13 Many studies have demonstrated its significant
association with high-risk clinicopathological characteris-
tics of PTC in overall analyses on tumors of all sizes.
Importantly, this mutation is associated with a markedly
increased rate of recurrence13 and even mortality14 of PTC.
Multivariate analyses showed that the prognostic power of
BRAF mutation for PTC was independent of the classical
clinicopathological risk factors.15,16 It was proposed that the
examination of BRAF mutation status could be helpful in
optimizing the risk management of PTMC.5,13,15 This
notion was supported by the recent demonstration in two
Italian studies that BRAF mutation in PTMC was associated
with aggressive clinicopathological characteristics, such as
extrathyroidal extension, lymph node metastasis, and
advanced TNM stages.17,18 In this issue of the Journal, Lee
and colleagues provide further evidence supporting the
prognostic potential of BRAF mutation in PTMC.19 In a
Chinese cohort of patients with PTMC that were carefully
characterized for clinicopathological characteristics, the
authors demonstrate a significant association of BRAF
mutation with extrathyroidal extension, lymph node
metastasis, and high TNM stages. BRAF mutation has been
widely demonstrated to promote the upregulation of many
tumor-promoting genes and the downregulation of tumor-
suppressor genes; it has also been shown to be involved in
the silencing of thyroid iodide-handling genes, impairing
the susceptibility of PTC to radioiodine treatment.13 These
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BRAF mutation-related molecular derangements are most
probably the underlying mechanism for BRAF mutation-
promoted aggressiveness of PTMC as well. However, Lee
and colleagues failed to find any case of ‘‘clinical’’ recur-
rence of PTMC over follow-up periods of 9 to 30 months,
so the predictive role of BRAF mutation for the recurrence
of PTMC could not be directly examined.19 Still, it is not
clear how the ‘‘clinical’’ recurrence was defined in this
study. The relatively short time of follow-up might be one
reason for the lack of any recurrence in this Chinese cohort
of patients with PTMC. Another explanation for the lack of
recurrence might be that the sensitive serum thyroglobulin
testing and radioiodine body scan, which are routinely used
for the detection of thyroid cancer persistence/recurrence in
Western countries, were apparently not used by Lee and
colleagues for the surveillance of PTC persistence/recur-
rence. Nevertheless, the highly significant association of
BRAF mutation with the classical high-risk clinicopatho-
logical factors in PTMC demonstrated by Lee and
colleagues again strongly suggests that, as in conventional
PTC,13 BRAF mutation is also a predictor for the aggres-
siveness of PTMC and may therefore indicate a poor
prognosis, such as the persistence/recurrence of this cancer.
Although one may have to wait for further studies on PTMC
to directly test this hypothesis, that it is highly likely to be
the case is suggested by the previous demonstration that
BRAF mutation predicted PTC recurrence in patients with
TNM stage I and II diseases, a group that included many
cases of PTMC.15,16 As PTMC is associated with an
extremely low mortality rate, the core of the clinical effort
in managing this cancer is to prevent, identify, and manage
its recurrence. BRAF mutation can be easily and reliably
analyzed on fine-needle aspiration biopsy specimens.13
Preoperative information of BRAF mutation status obtained
through analysis of ultrasonography-guided fine-needle
biopsy specimens of PTMC could be very valuable in
guiding the management of this cancer at various stages,
helping determine the extent of initial surgical treatment,
the need for radioiodine ablation, and the level of vigilance
in the subsequent follow-up of the patient.
Recent decades have seen a rapid rise in the incidence of
thyroid cancer worldwide, which is virtually exclusively
attributable to an increased diagnosis of PTC.20–22 Given
that PTC accounts for[80% of all thyroid cancers and that
nearly 50% of the new cases of PTC are PTMC,20,21 a
major challenge in today’s thyroid cancer medicine is how
to appropriately manage the already large and still
increasing number of PTMC cases. Although the overall
prevalence of BRAF mutation in PTC is relatively high,
around 45% on average,13 the prevalence of this mutation
in PTMC is generally much lower in many parts of the
world17,18,23,24 and as low as 18% in PTMC of \5 mm in
size.24 Excluding the areas in Korea where the BRAF
mutation in PTC is somehow unusually high, the preva-
lence of BRAF mutation in PTC with TNM stages I and II,
which consist largely of small tumors, is around 30%.13
With the relatively low prevalence of BRAF mutation in
PTMC, it seems feasible to treat more aggressively the
one-third of PTMC patients that are BRAF mutation-posi-
tive and may be thus prone to a poor prognosis. The
remaining cases (majority) of the PTMC patients that are
BRAF mutation-negative may be relatively conservatively
managed unless indicated otherwise by other factors. The
current risk management of PTMC is virtually exclusively
based on clinicopathological criteria. By adding BRAF
mutation as a new dimension in risk stratification of
PTMC, the appropriate extent of surgical and medical
treatments of this cancer may now be better determined.
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